Drugs / Omburtamab
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05063357 | Mar 2022 → Mar 2026 | diffuse intrinsic pontine glioma | Y-mAbs Therapeutics | Withdrawn | No outcome recorded |
| Phase 1 | NCT01502917 | Dec 2011 → Jan 2022 | diffuse intrinsic pontine glioma | Y-mAbs Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01099644 | Apr 2010 → Jun 2019 | peritoneum cancer | Y-mAbs Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT00089245 | Feb 2004 → Feb 2022 | central nervous system neoplasm, neuroblastoma, sarcoma | Y-mAbs Therapeutics | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04743661 | Apr 2022 → Mar 2026 overdue | ependymoma, medulloblastoma | Pediatric Brain Tumor Consortium | Active not recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Omburtamab | “In this phase I study, we evaluated the safety, pharmacokinetics, and biodistribution of intraperitoneal (IP) radioimmunotherapy (RIT) with the anti-B7H3 murine monoclonal...” PMID 33119478 ↗ Oct 20204“Patients will be injected, intrathecally, with 2 mCi 131I-Omburtamab during week 1 of a 5 week cycle.” NCT00089245 ↗ |
| Known as | 124I-omburtamab | “The purpose of this study is to test the safety of a new method to treat Diffuse Intrinsic Pontine Glioma (DIPG). The researchers will use "convection-enhanced delivery" (CED)...” NCT01502917 ↗ |
| Known as | 131I-Omburtamab | “In this phase I study, we evaluated the safety, pharmacokinetics, and biodistribution of intraperitoneal (IP) radioimmunotherapy (RIT) with the anti-B7H3 murine monoclonal...” PMID 33119478 ↗ Oct 20202“The dose used in this study is 50 mCi 131IOmburtamab, (averaging 5 mCi/mg Omburtamab at 50 mCi dose) which will be administered to each patient during week 2 of a 5 week cycle.” NCT00089245 ↗ “intraOmmaya 131I-omburtamab (8H9), an antiB7-H3 antibody” PMID 33047248 ↗ Oct 2020 |
| Known as | 8H9 | “intraOmmaya 131I-omburtamab (8H9), an antiB7-H3 antibody” PMID 33047248 ↗ Oct 2020 |
| Action | Deplete | “124I-omburtamab sticks to parts of tumor cells and can cause the tumor cells to die from radiation.” NCT01502917 ↗ |
| Modality | Monoclonal antibody | “the anti-B7H3 murine monoclonal antibody omburtamab” PMID 36371226 ↗ Nov 2022 |
| Route | Intrathecal | “Patients will be injected, intrathecally” NCT00089245 ↗ |
| Target | CD276 | “Omburtamab is a murine IgG1 monoclonal antibody (mAb) against B7-H3 (CD276)” NCT04743661 ↗ |